Why the study?
Despite immunoglobulin therapy, some Kawasaki disease patients develop progressive coronary injury, yet mechanisms linking immune activation, metabolic remodeling, and RAAS-mediated vascular inflammation remain unclear.
The identification of the S100A8/A9-ACE-angiotensin axis provides a novel immune-metabolic-vascular framework for understanding coronary injury in Kawasaki disease and highlights potential biomarkers for risk stratification.
Answers are grounded in this paper and cite their sources.
May suggest RAAS targets in refractory Kawasaki coronary lesions; leaves open causal validation in prospective studies.
Background Kawasaki disease is an acute pediatric vasculitis and a leading cause of coronary artery lesions. Despite immunoglobulin therapy, some patients develop progressive coronary injury, yet mechanisms linking immune activation, metabolic remodeling, and renin-angiotensin-aldosterone system-mediated vascular inflammation remain unclear. Methods We applied an integrative multi-omics approach combining bulk and single-cell transcriptomics, genetic association, Mendelian randomization, and molecular docking. Systems analyses, including gene set enrichment and co-expression networks, were used to identify disease-associated pathways and genetic signals related to disease susceptibility. Results We identified an S100A8/A9-ACE-angiotensin axis that integrates immune activation, metabolic remodeling, and vascular inflammation in Kawasaki disease. Genetic analyses suggested that genetically predicted increases in S100A9 and ACE expression were associated with higher Kawasaki disease susceptibility. This axis was upregulated in patients with coronary lesions. Molecular docking identified computationally favorable binding poses among angiotensin, S100A proteins, and ACE, providing structural hypotheses that require biochemical and cellular validation. Conclusion The S100A8/A9-ACE-angiotensin axis may represent an important regulatory axis associated with coronary injury in Kawasaki disease. This RAAS-centered immune-metabolic-vascular framework identifies candidate biomarkers for coronary risk stratification and may guide future therapeutic evaluation in high-risk Kawasaki disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: